Stock Track | Adaptive Biotechnologies Soars 6.25% After-Hours on Strong Q4 Results and Positive Guidance

Stock Track05:50

Adaptive Biotechnologies Corp's stock surged 6.25% in after-hours trading following the release of its fourth-quarter 2025 financial results that significantly exceeded analyst expectations.

The biotechnology company reported Q4 revenue of $71.68 million, representing a 51% year-over-year increase and beating the consensus estimate of $59.39 million. More notably, Adaptive Biotechnologies achieved adjusted EBITDA of $4.10 million, dramatically outperforming analyst expectations of a $7.45 million loss and marking a positive turnaround for the company's financial performance.

The company's MRD (minimal residual disease) business showed particularly strong results, with revenue growing 54% in Q4 and contributing 86% of total revenue. Adaptive Biotechnologies also provided optimistic guidance for 2026, expecting MRD revenue between $255 million and $265 million. Additional positive developments included expanded Medicare coverage for the clonoSEQ test in mantle cell lymphoma and new data licensing agreements with Pfizer, contributing to investor optimism about the company's growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121542652?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 05:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121542652","market":"sg","top_or_hot":-1,"title":"Stock Track | Adaptive Biotechnologies Soars 6.25% After-Hours on Strong Q4 Results and Positive Guidance","media":"Stock Track","content":"<p>Adaptive Biotechnologies Corp's stock surged 6.25% in after-hours trading following the release of its fourth-quarter 2025 financial results that significantly exceeded analyst expectations.</p><p>The biotechnology company reported Q4 revenue of $71.68 million, representing a 51% year-over-year increase and beating the consensus estimate of $59.39 million. More notably, Adaptive Biotechnologies achieved adjusted EBITDA of $4.10 million, dramatically outperforming analyst expectations of a $7.45 million loss and marking a positive turnaround for the company's financial performance.</p><p>The company's MRD (minimal residual disease) business showed particularly strong results, with revenue growing 54% in Q4 and contributing 86% of total revenue. Adaptive Biotechnologies also provided optimistic guidance for 2026, expecting MRD revenue between $255 million and $265 million. Additional positive developments included expanded Medicare coverage for the clonoSEQ test in mantle cell lymphoma and new data licensing agreements with Pfizer, contributing to investor optimism about the company's growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Adaptive Biotechnologies Soars 6.25% After-Hours on Strong Q4 Results and Positive Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Adaptive Biotechnologies Soars 6.25% After-Hours on Strong Q4 Results and Positive Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-06 05:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Adaptive Biotechnologies Corp's stock surged 6.25% in after-hours trading following the release of its fourth-quarter 2025 financial results that significantly exceeded analyst expectations.</p><p>The biotechnology company reported Q4 revenue of $71.68 million, representing a 51% year-over-year increase and beating the consensus estimate of $59.39 million. More notably, Adaptive Biotechnologies achieved adjusted EBITDA of $4.10 million, dramatically outperforming analyst expectations of a $7.45 million loss and marking a positive turnaround for the company's financial performance.</p><p>The company's MRD (minimal residual disease) business showed particularly strong results, with revenue growing 54% in Q4 and contributing 86% of total revenue. Adaptive Biotechnologies also provided optimistic guidance for 2026, expecting MRD revenue between $255 million and $265 million. Additional positive developments included expanded Medicare coverage for the clonoSEQ test in mantle cell lymphoma and new data licensing agreements with Pfizer, contributing to investor optimism about the company's growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADPT","symbol_name":"Adaptive Biotechnologies Corp","start_time":0,"source_url":"","article_id":"1121542652","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121542652","pubTimestamp":1770328240,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Adaptive Biotechnologies Corp's stock surged 6.25% in after-hours trading following the release of its fourth-quarter 2025 financial results that significantly exceeded analyst expectations.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADPT":"Adaptive Biotechnologies Corp"},"translate_title":"个股追踪|Adaptive Biotechnologies盘后大涨6.25%得益于强劲的Q4业绩和积极指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADPT":1},"content_text":"Adaptive Biotechnologies Corp's stock surged 6.25% in after-hours trading following the release of its fourth-quarter 2025 financial results that significantly exceeded analyst expectations.The biotechnology company reported Q4 revenue of $71.68 million, representing a 51% year-over-year increase and beating the consensus estimate of $59.39 million. More notably, Adaptive Biotechnologies achieved adjusted EBITDA of $4.10 million, dramatically outperforming analyst expectations of a $7.45 million loss and marking a positive turnaround for the company's financial performance.The company's MRD (minimal residual disease) business showed particularly strong results, with revenue growing 54% in Q4 and contributing 86% of total revenue. Adaptive Biotechnologies also provided optimistic guidance for 2026, expecting MRD revenue between $255 million and $265 million. Additional positive developments included expanded Medicare coverage for the clonoSEQ test in mantle cell lymphoma and new data licensing agreements with Pfizer, contributing to investor optimism about the company's growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121542652","isCrawlerRequest":true}